Next Article in Journal
Roles of Nitric Oxide and Asymmetric Dimethylarginine in Pregnancy and Fetal Programming
Next Article in Special Issue
Mast Cells in the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Previous Article in Journal
Chronic Supplementation of Paeonol Combined with Danshensu for the Improvement of Vascular Reactivity in the Cerebral Basilar Artery of Diabetic Rats
Previous Article in Special Issue
Experimental and Therapeutic Opportunities for Stem Cells in Multiple Sclerosis
Article Menu

Export Article

Open AccessReview
Int. J. Mol. Sci. 2012, 13(11), 14579-14605; doi:10.3390/ijms131114579

Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting Inflammatory Mechanisms of both the Innate and Adaptive Immune System?

Department of Biomedicine, Aarhus University, Wilhelm Meyers Allé 4, Building 1242, DK-8000, Aarhus C, Denmark
*
Author to whom correspondence should be addressed.
Received: 29 September 2012 / Revised: 23 October 2012 / Accepted: 5 November 2012 / Published: 9 November 2012
(This article belongs to the Special Issue Recent Advances in the Research of Multiple Sclerosis)
View Full-Text   |   Download PDF [2177 KB, uploaded 19 June 2014]   |  

Abstract

Multiple sclerosis is a disease of the central nervous system, resulting in the demyelination of neurons, causing mild to severe symptoms. Several anti-inflammatory treatments now play a significant role in ameliorating the disease. Glatiramer acetate (GA) is a formulation of random polypeptide copolymers for the treatment of relapsing-remitting MS by limiting the frequency of attacks. While evidence suggests the influence of GA on inflammatory responses, the targeted molecular mechanisms remain poorly understood. Here, we review the multiple pharmacological modes-of-actions of glatiramer acetate in treatment of multiple sclerosis. We discuss in particular a newly discovered interaction between the leukocyte-expressed integrin αMβ2 (also called Mac-1, complement receptor 3, or CD11b/CD18) and perspectives on the GA co-polymers as an influence on the function of the innate immune system. View Full-Text
Keywords: glatiramer acetate; copaxone; biosimilar; integrin; immunotherapy glatiramer acetate; copaxone; biosimilar; integrin; immunotherapy
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Jalilian, B.; Einarsson, H.B.; Vorup-Jensen, T. Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting Inflammatory Mechanisms of both the Innate and Adaptive Immune System? Int. J. Mol. Sci. 2012, 13, 14579-14605.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top